BMS-690514 clinical trials
Also written BMS-690514.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2004
How each study uses BMS-690514 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
9 studies that test it; most in 2007 (3)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 0
Often tested with
Tested in the same studies.
Lapatinib (1) · FOLFIRI-Ziv-aflibercept Regimen (1) · FOLFIRI Regimen (1) · Folfox protocol (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses BMS-690514 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Phase I Study of BMS-690514 in Combination With Paclitaxel and CarboplatinCompletedPhase 1Bristol-Myers SquibbNCT00420186Written as BMS-690514
- Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior ResponseCompletedPhase 2Bristol-Myers SquibbNCT01167244Written as BMS-690514
- Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast CancerCompletedPhase 2Bristol-Myers SquibbNCT01068704Written as BMS-690514
- A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLCCompletedPhase 2Bristol-Myers SquibbNCT00743938Written as BMS-690514
- Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOXCompletedPhase 1Bristol-Myers SquibbNCT00479583Written as BMS-690514 / FOLFIRI
- A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid TumorsCompletedPhase 1Bristol-Myers SquibbNCT00329004Written as BMS-690514
- BMS-599626 in Patients With Advanced Solid MalignanciesCompletedPhase 1Bristol-Myers SquibbNCT00095537Written as panHer
- Phase I Study of BMS-690514 in Japanese Patients With Solid TumorsCompletedPhase 1Bristol-Myers SquibbNCT00516451Written as BMS-690514
- Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male SubjectsCompletedPhase 1Bristol-Myers SquibbNCT00578916Written as EVRI (BMS-690514)
Codes
What other systems call BMS-690514 · ClinicalTrials.gg INT005702
- UNII (FDA) VKU5X213Q7BMS-690514Confirmed FDA, Wikidata
- Wikidata Q27075363bms-690514Confirmed FDA, Wikidata
- NCI Thesaurus C68832Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514One source FDA
- DrugBank DB11665One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | VKU5X213Q7 | BMS-690514 | Confirmed FDA, Wikidata |
| Wikidata | Q27075363 | bms-690514 | Confirmed FDA, Wikidata |
| NCI Thesaurus | C68832 | Pan HER/VEGFR2 Receptor Tyrosine Kinase Inhibitor BMS-690514 | One source FDA |
| DrugBank | DB11665 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.